Raabya Rossenkhan
YOU?
Author Swipe
View article: VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials Open
Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bNAb VRC01 blocked acquisition by VRC01-sensitive …
View article: Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV Infection
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV Infection Open
Understanding the selective forces acting upon HIV early in infection is crucial to design prevention strategies. By leveraging deep sequencing and the short diagnostic intervals of the FRESH and RV217 cohorts (median 4 days) between the l…
View article: Bayesian estimation of HIV acquisition dates for prevention trials
Bayesian estimation of HIV acquisition dates for prevention trials Open
Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly n…
View article: Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials Open
In the HIV antibody mediated prevention (AMP) trials, the broadly neutralizing antibody VRC01 demonstrated protective efficacy against new diagnoses with susceptible HIV strains. To understand how VRC01 shaped breakthrough infections, we p…
View article: Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features Open
In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition diagnosis varied acco…
View article: Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition Open
View article: Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
View article: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
View article: Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
View article: Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features Open
In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition diagnosis varied acco…
View article: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematic…
View article: Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition Open
The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted se…
View article: Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition Open
Was provided by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) (UM1 AI068614, to the HIV Vaccine Trials Network [HVTN]; UM1 AI068635, to the HVTN Statistical Data and Management Center [SDM…
View article: Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition Open
The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted se…
View article: Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition
Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition Open
View article: B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin
B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin Open
Tissue-based T cells are important effectors in the prevention and control of mucosal viral infections; less is known about tissue-based B cells. We demonstrate that B cells and antibody-secreting cells (ASCs) are present in inflammatory i…
View article: B cells and HSV-specific antibodies respond to HSV-2 reactivation in skin
B cells and HSV-specific antibodies respond to HSV-2 reactivation in skin Open
Tissue-based T cells increasingly have been shown to be important effectors in the control and prevention of mucosal viral infections – less is known about tissue-based B cells. We demonstrate that B cells and antibody-secreting cells (ASC…
Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand Open
View article: Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment Open
Knowledge of the time of HIV-1 infection and the multiplicity of viruses that establish HIV-1 infection is crucial for the in-depth analysis of clinical prevention efficacy trial outcomes. Better estimation methods would improve the abilit…